

Todd J Anderson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8977128/publications.pdf>

Version: 2024-02-01

64
papers

2,657
citations

393982

19
h-index

189595

50
g-index

65
all docs

65
docs citations

65
times ranked

4381
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2016, 32, 1263-1282.	0.8	775
2	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Canadian Journal of Cardiology, 2021, 37, 1129-1150.	0.8	367
3	Microvascular Function Predicts Cardiovascular Events in Primary Prevention. Circulation, 2011, 123, 163-169.	1.6	334
4	Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Failure Reviews, 2003, 8, 71-86.	1.7	132
5	Effect of Evolocumab on Coronary Plaque Composition. Journal of the American College of Cardiology, 2018, 72, 2012-2021.	1.2	95
6	Aerobic exercise improves cognition and cerebrovascular regulation in older adults. Neurology, 2020, 94, e2245-e2257.	1.5	80
7	Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2254-2259.	1.1	68
8	Common Carotid Intima-Media Thickness Relates to Cardiovascular Events in Adults Aged <45 Years. Hypertension, 2015, 65, 707-713.	1.3	60
9	Assessment and Prognosis of Peripheral Artery Measures of Vascular Function. Progress in Cardiovascular Diseases, 2015, 57, 497-509.	1.6	52
10	The New Dyslipidemia Guidelines: What Is the Debate?. Canadian Journal of Cardiology, 2015, 31, 605-612.	0.8	46
11	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). American Heart Journal, 2016, 176, 83-92.	1.2	45
12	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. Cmaj, 2018, 190, E1192-E1206.	0.9	39
13	Coronary endothelial dysfunction in non-obstructive coronary artery disease: Risk, pathogenesis, diagnosis and therapy. Vascular Medicine, 2016, 21, 146-155.	0.8	38
14	Clinical Factors Associated With High-Risk Carotid Plaque Features as Assessed by Magnetic Resonance Imaging in Patients With Established Vascular Disease (from the AIM-HIGH Study). American Journal of Cardiology, 2014, 114, 1412-1419.	0.7	33
15	Lp(a) (Lipoprotein(a)) Levels Predict Progression of Carotid Atherosclerosis in Subjects With Atherosclerotic Cardiovascular Disease on Intensive Lipid Therapy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 673-678.	1.1	32
16	The fate of endothelial function testing: rationale and design of the Firefighters And Their Endothelium (FATE) study. Canadian Journal of Cardiology, 2003, 19, 61-6.	0.8	31
17	Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy. Journal of the American College of Cardiology, 2003, 41, 420-425.	1.2	29
18	Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels. ESC Heart Failure, 2017, 4, 301-311.	1.4	28

#	ARTICLE	IF	CITATIONS
19	The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. BMC Cardiovascular Disorders, 2014, 14, 91.	0.7	27
20	Layer-specific strain in patients with heart failure using cardiovascular magnetic resonance: not all layers are the same. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 81.	1.6	21
21	Frailty Trajectories After Treatment for Coronary Artery Disease in Older Patients. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 230-238.	0.9	20
22	Treatment and Low-Density Lipoprotein Cholesterol Management in Patients Diagnosed With Clinical Atherosclerotic Cardiovascular Disease in Alberta. Canadian Journal of Cardiology, 2019, 35, 884-891.	0.8	20
23	Barriers and Facilitators to Using Statins: A Qualitative Study With Patients and Family Physicians. CJC Open, 2020, 2, 530-538.	0.7	20
24	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE): 2014 update. Cmaj, 2014, 186, 1299-1305.	0.9	19
25	Human intermittent hypoxia-induced respiratory plasticity is not caused by inflammation. European Respiratory Journal, 2015, 46, 1072-1083.	3.1	16
26	Impact of clinical presentation and presence of coronary sclerosis on long-term outcome of patients with non-obstructive coronary artery disease. BMC Cardiovascular Disorders, 2018, 18, 173.	0.7	15
27	Cerebrovascular and ventilatory responses to acute isocapnic hypoxia in healthy aging and lung disease: effect of vitamin C. Journal of Applied Physiology, 2015, 119, 363-373.	1.2	14
28	Association of Apolipoproteins B and A-1 With Markers of Vascular Health or Cardiovascular Events. Canadian Journal of Cardiology, 2017, 33, 1305-1311.	0.8	14
29	Cardiac remodelling predicts outcome in patients with chronic heart failure. ESC Heart Failure, 2021, 8, 5352-5362.	1.4	12
30	Endothelial cell dysfunction in type I and II diabetes: The cellular basis for dysfunction. Drug Development Research, 2003, 58, 28-41.	1.4	11
31	Role of Vascular Function in Predicting Arteriovenous Fistula Outcomes: An Observational Pilot Study. Canadian Journal of Kidney Health and Disease, 2015, 2, 55.	0.6	11
32	Cardiometabolic risk factors predict cerebrovascular health in older adults: results from the <i>Brain in Motion</i> study. Physiological Reports, 2016, 4, e12733.	0.7	11
33	Impact of contrast echocardiography on accurate discrimination of specific degree of left ventricular systolic dysfunction and comparison with cardiac magnetic resonance imaging. Echocardiography, 2018, 35, 1746-1754.	0.3	10
34	Left atrial remodelling, mid-regional pro-atrial natriuretic peptide, and prognosis across a range of ejection fractions in heart failure. European Heart Journal Cardiovascular Imaging, 2021, 22, 220-228.	0.5	10
35	Vascular responses to hypoxia are not impaired in obstructive sleep apnoea patients free of overt cardiovascular disease. Experimental Physiology, 2019, 104, 580-600.	0.9	9
36	New Hope for Lipid-Lowering Beyond Statins: Effect of IMPROVE-IT on Understanding and Implementation of Atherosclerosis Prevention. Canadian Journal of Cardiology, 2015, 31, 585-587.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Colchicine for Prevention of Atherothrombotic Events in Patients With Coronary Artery Disease: Review and Practical Approach for Clinicians. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1837-1845.	0.8	8
38	Aerobic exercise training in older men and women—Cerebrovascular responses to submaximal exercise: Results from the Brain in Motion study. <i>Physiological Reports</i> , 2022, 10, e15158.	0.7	8
39	Cerebrovascular Responsiveness to Hypercapnia Is Stable over Six Months in Older Adults. <i>PLoS ONE</i> , 2015, 10, e0143059.	1.1	7
40	Statin Prescriptions for High-Risk Patients Are Increased by Laboratory-Initiated Framingham Risk Scores: A Quality-Improvement Initiative. <i>Canadian Journal of Cardiology</i> , 2017, 33, 682-684.	0.8	7
41	Incidence and Prognostic Implications of Late Bleeding After Myocardial Infarction or Unstable Angina According to Treatment Strategy. <i>Canadian Journal of Cardiology</i> , 2017, 33, 998-1005.	0.8	7
42	Circulating troponin and further left ventricular ejection fraction improvement in patients with previously recovered left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 2725-2733.	1.4	7
43	Depressive symptoms and functional decline following coronary interventions in older patients with coronary artery disease: a prospective cohort study. <i>BMC Psychiatry</i> , 2016, 16, 277.	1.1	6
44	Variables Associated With Cardiac Surgical Waitlist Mortality From a Population-Based Cohort. <i>Canadian Journal of Cardiology</i> , 2019, 35, 61-67.	0.8	6
45	Importance of Optimization of Cardiovascular Risk Factors and Lifestyle Behaviours. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1221-1222.	0.8	5
46	Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1413-1419.	0.6	5
47	Large and small vessel vasoconstriction following coronary artery stenting. <i>International Journal of Cardiology</i> , 2006, 113, 61-65.	0.8	4
48	Increased ventilatory response to carbon dioxide in COPD patients following vitamin C administration. <i>ERJ Open Research</i> , 2015, 1, 00017-2015.	1.1	3
49	Metabolic Syndrome Sinkholes: What to Do When Occam's Razor Gets Blunted. <i>Canadian Journal of Cardiology</i> , 2015, 31, 601-604.	0.8	3
50	Optimal Low-Density Lipoprotein Cholesterol for Cardiovascular Prevention: How Low Should We Go?. <i>Canadian Journal of Cardiology</i> , 2017, 33, 405-408.	0.8	3
51	Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 534-541.	1.0	3
52	Impact of nocturnal oxygen and CPAP on the ventilatory response to hypoxia in OSA patients free of overt cardiovascular disease. <i>Experimental Neurology</i> , 2021, 346, 113852.	2.0	3
53	Impact of intermittent hypoxia on human vascular responses during sleep. <i>Experimental Neurology</i> , 2022, 347, 113897.	2.0	3
54	Anti-IL-1/4llergic hormone and vascular dysfunction in women with chronic kidney disease. <i>Physiological Reports</i> , 2022, 10, e15154.	0.7	3

#	ARTICLE	IF	CITATIONS
55	Care gaps in achieving cholesterol targets in people with diabetes: A population-based study in a universal health care setting. <i>Diabetes Research and Clinical Practice</i> , 2022, 184, 109177.	1.1	3
56	Evaluation of a Candida Antigen Detection Method (Cand-Tec): Experience from a University Teaching Hospital. <i>Canadian Journal of Infectious Diseases & Medical Microbiology</i> , 1992, 3, 167-172.	0.3	2
57	Chest Pain After Percutaneous Coronary Intervention: More Than Meets the Eye. <i>Canadian Journal of Cardiology</i> , 2015, 31, 960-962.	0.8	2
58	C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100091.	1.3	2
59	Laboratory reporting of framingham risk score increases statin prescriptions in at-risk patients. <i>Clinical Biochemistry</i> , 2021, 96, 1-7.	0.8	2
60	Bringing Structure to the Art of Lipid-Lowering Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2422-2424.	1.2	1
61	Understanding Coronary Microvascular Disease—New Insights for a Confusing and Underdiagnosed Entity. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1199-1202.	0.8	1
62	Patterns of Left-Ventricular Function Assessment in Patients With Acute Coronary Syndromes. <i>CJC Open</i> , 2021, 3, 733-740.	0.7	1
63	Myocardial Microvascular Physiology in Acute and Chronic Coronary Syndromes, Aortic Stenosis, and Heart Failure. <i>Journal of Interventional Cardiology</i> , 2022, 2022, 1-7.	0.5	0
64	Abstract 10590: Trends in Major Adverse Cardiac Events During the Covid-19 Pandemic in Alberta, Canada. <i>Circulation</i> , 2021, 144, .	1.6	0